# AgomAb Therapeutics NV: Form 20-F for the period ended Dec 31, 2025

- Company: [AgomAb Therapeutics NV](/companies/agmb.md) (CIK 2020932)
- Form: 20-F
- Filed: 2026-04-23
- Accepted by EDGAR: Apr 23, 2026, 17:17 ET
- Period: 2025-12-31
- Accession: 0001104659-26-047872
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/2020932/000110465926047872/agmb-20251231x20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/2020932/000110465926047872/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Shares outstanding | at 2025-12-31 | 34,167,168 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/2020932/000110465926047872/agmb-20251231x20f.htm

Filed Apr 23, 2026.
Source: SEC EDGAR, the filing index for accession 0001104659-26-047872. Last ingested by Listed: Nov 6, 2026, 11:21 ET. No prices; not investment advice.